Registro:

Referencias:

• Salamone, J.D., Correa, M., Mingote, S.M., Weber, S.M., Beyond the reward hypothesis: Alternative functions of nucleus accumbens dopamine (2005) Curr. Opin. Pharmacol., 5, pp. 34-41
• Palmiter, R.D., Dopamine signaling in the dorsal striatum is essential for motivated behaviors: Lessons from dopamine-deficient mice (2008) Ann. N.Y. Acad. Sci., 1129, pp. 35-46
• Missale, C., Nash, S.R., Robinson, S., Jaber, M., Caron, M.G., Dopamine receptors: From structure to function (1998) Physiol. Rev., 78, pp. 189-225
• Kelly, M.A., Rubinstein, M., Phillips, T.J., Lessov, C.N., Burkhart-Kasch, S., Zhang, G., Bunzow, J.R., Low, M.J., Locomotor activity in D2 dopamine receptordeficient mice is determined by gene dosage, genetic background, and developmental adaptations (1998) J. Neurosci., 18, pp. 3470-3479
• Morgan, D., Grant, K.A., Gage, H.D., Mach, R.H., Kaplan, J.R., Prioleau, O., Nader, S.H., Nader, M.A., Social dominance in monkeys: Dopamine D2 receptors and cocaine self-administration (2002) Nat. Neurosci., 5, pp. 169-174
• Ben-Jonathan, N., Hnasko, R., Dopamine as a prolactin inhibitor (2001) Endocr Rev., 22, pp. 724-763
• Garcia-Tornadu, I., Risso, G., Perez-Millan, M.I., Noain, D., Diaz-Torga, G.S., Low, M.J., Rubinstein, M., Becu-Villalobos, D., Neurotransmitter modulation of the GHRH-GH axis (2010) Front Horm Res., 38, pp. 59-69
• Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G., Dopamine receptors: From structure to function (1998) Physiol. Rev., 78, pp. 189-225
• Guiramand, J., Montmayeur, J.P., Ceraline, J., Bhatia, M., Borrelli, E., Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins (1995) J. Biol. Chem., 270, pp. 7354-7358
• Guivarc'h, D., Vernier, P., Vincent, J.D., Sex steroid hormones change the differential distribution of the isoforms of the D2 dopamine receptor messenger RNA in the rat brain (1995) Neuroscience, 69, pp. 159-166
• Iaccarino, C., Samad, T.A., Mathis, C., Kercret, H., Picetti, R., Borrelli, E., Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs (2002) Proc. Natl. Acad. Sci. USA, 99, pp. 14530-14535
• De Mei, C., Ramos, M., Iitaka, C., Borrelli, E., Getting specialized: Presynaptic and postsynaptic dopamine D2 receptors (2009) Curr. Opin. Pharmacol., 9, pp. 53-58
• Ben-Jonathan, N., LaPensee, C.R., LaPensee, E.W., What can we learn from rodents about prolactin in humans? (2008) Endocr Rev., 29, pp. 1-41
• Kelly, M.A., Rubinstein, M., Asa, S.L., Zhang, G., Saez, C., Bunzow, J.R., Allen, R.G., Low, M.J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptordeficient mice (1997) Neuron, 19, pp. 103-113
• Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355
• Cristina, C., García-Tornadú, I., Diaz-Torga, G., Rubinstein, M., Low, M.J., Becu-Villalobos, D., The dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma (2006) Front Horm Res., 35, pp. 50-63
• Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146, pp. 2952-2962
• Cristina, C., Diaz-Torga, G.S., Goya, R.G., Kakar, S.S., Perez-Millan, M.I., Passos, V.Q., Gianella-Neto, D., Becu-Villalobos, D., PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes (2007) Mol. Cancer, 6, p. 4
• Cristina, C., Diaz-Torga, G., Gongora, A., Guida, M.C., Perez-Millan, M.I., Baldi, A., Becu-Villalobos, D., Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice (2007) Am. J. Physiol. Endocrinol. Metab., 293, pp. E1341-E1351
• Hentges, Boyadjieva, N., Sarkar, D.K., Transforming growth factor-β3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells (2000) Endocrinology, 141, pp. 859-867
• Pastorcic, M., De, A., Boyadjieva, N., Vale, W., Sarkar, D.K., Reduction in the expression and action of transforming growth factor-β1 on lactotropes during estrogen-induced tumorigenesis (1995) Cancer Res., 55, pp. 4892-4898
• Fumagalli, F., Bedogni, F., Maragnoli, M.E., Gennarelli, M., Perez, J., Racagni, G., Riva, M.A., Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus (2003) J. Neurosci. Res., 74, pp. 74-80
• Yamada, S., Takada, K., Angiogenesis in pituitary adenomas (2003) Microsc Res. Tech., 60, pp. 236-243
• Friedman, E., Adams, H.F., Hoog, A., Gejman, P.V., Carson, E., Larsson, C., De Marco, L., Nordenskjöld, M., Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors (1994) J. Clin. Endocrinol. Metab., 78, pp. 568-574
• Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D., Jaquet, P., Enjalbert, A., Decreased expression of the two D2 dopamine receptor isoforms in bromocriptineresistant prolactinomas (1994) Neuroendocrinology, 60, pp. 314-322
• Pellegrini, I., Rasolonjanahary, R., Gunz, G., Bertrand, P., Delivet, S., Jedynak, C.P., Kordon, C., Enjalbert, A., Resistance to bromocriptine in prolactinomas (1989) J. Clin. Endocrinol. Metab., 69, pp. 500-509
• Komorowski, J., Jankewicz, J., Stepien, H., Vascular endothelial growth factor, basic fibroblast growth factor and soluble interleukin-2 receptor concentrations in peripheral blood as markers of pituitary tumours (2000) Cytobios, 101, pp. 151-159
• Lohrer, P., Gloddek, J., Hopfner, U., Losa, M., Uhl, E., Pagotto, U., Stalla, G.K., Renner, U., Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro (2001) Neuroendocrinology, 74, pp. 95-105
• Cristina, C., Perez-Millan, M.I., Luque, G., Dulce, R.A., Sevlever, G., Berner, S.I., Becu-Villalobos, D., VEGF and CD31 association in pituitary adenomas (2010) Endocr Pathol., 21, pp. 154-160
• Jugenburg, M., Kovacs, K., Stefaneanu, L., Scheithauer, B.W., Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study (1995) Endocr Pathol., 6, pp. 115-124
• De La Torre, N.G., Wass, J.A., Turner, H.E., Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas (2004) Front Horm Res., 32, pp. 133-145
• Muller, E.E., Locatelli, V., Cocchi, D., Neuroendocrine control of growth hormone secretion (1999) Physiol. Rev., 79, pp. 511-607
• Kitajima, N., Chihara, K., Hiromi, H., Okimura, Y., Fujii, Y., Sato, M., Shakutsui, S., Fufita, T., Effects of dopamine on immunoreactive growth hormone-releasing factor and somatostatin secretion from rat hypothalamic slices perfused in vitro (1989) Endocrinology, 124, pp. 69-76
• Bluet-Pajot, M.T., Mounier, F., Durand, D., Kordon, C., Involvement of dopamine D1 receptors in the control of growth hormone secretion in the rat (1990) J. Endocrinol., 127, pp. 191-196
• Diaz-Torga, G., Feierstein, C., Libertun, C., Gelman, D., Kelly, M.A., Low, M.J., Rubinstein, M., Becu-Villalobos, D., Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice (2002) Endocrinology, 143, pp. 1270-1279
• Simonian, S.X., Murray, H.E., Gillies, G.E., Herbison, A.E., Estrogen-dependent ontogeny of sex differences in somatostatin neurons of the hypothalamic periventricular nucleus (1998) Endocrinology, 139, pp. 1420-1428
• Cuttler, L., Welsh, J.B., Szabo, M., The effect of age on somatostatin suppression of basal, growth hormone (GH)-releasing factorstimulated and dibutyryl adenosine 3′-5′ - Monophosphate-stimulated GH release from rat pituitary cells in monolayer culture (1986) Endocrinology, 119, pp. 152-158
• Garcia-Tornadu, I., Rubinstein, M., Gaylinn, B.D., Hill, D., Arany, E., Low, M.J., Diaz-Torga, G., Becu-Villalobos, D., GH in the dwarf dopaminergic D2 receptor knockout mouse: Somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin (2006) J. Endocrinol., 190, pp. 611-619
• Al Shawi, R., Wallace, H., Harrison, S., Jones, C., Johnson, D., Bishop, J.O., Sexual dimorphism and growth hormone regulation of a hybrid gene in transgenic mice (1992) Mol. Endocrinol., 6, pp. 181-190
• Lin, S.C., Lin, C.R., Gukovsky, I., Lusis, A.J., Sawchenko, P.E., Rosenfeld, M.G., Molecular basis of the little mouse phenotype and implications for cell type-specific growth (1993) Nature, 364, pp. 208-213
• Cella, S.G., Locatelli, V., Broccia, M.L., Menegola, E., Giavini, E., De Gennaro, C.V., Torsello, A., Muller, E.E., Long-term changes of somatotrophic function induced by deprivation of growth hormone-releasing hormone during the fetal life of the rat (1994) J. Endocrinol., 140, pp. 111-117
• Robinson, G.M., Spencer, G.S., Berry, C.J., Dobbie, P.M., Hodgkinson, S.C., Bass, J.J., Evidence of a role for growth hormone, but not for insulinlike growth factors-I and-II in the growth of the neonatal rat (1993) Biol. Neonate, 64, pp. 158-165
• Maheshwari, H.G., Silverman, B.L., Dupuis, J., Baumann, G., Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: Dwarfism of Sindh (1998) J. Clin. Endocrinol. Metab., 83, pp. 4065-4074
• Huseman, C.A., Hassing, J.M., Evidence for dopaminergic stimulation of growth velocity in some hypopituitary children (1984) J. Clin. Endocrinol. Metab., 58, pp. 419-425
• Miyake, H., Nagashima, K., Onigata, K., Nagashima, T., Takano, Y., Morikawa, A., Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature (1999) J. Hum. Genet., 44, pp. 26-29
• Mann, K., Rossbach, W., Muller, M.J., Muller-Siecheneder, F., Pott, T., Linde, I., Dittmann, R.W., Hiemke, C., Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine (2006) Psychoneuroendocrinology, 31, pp. 256-264
• Ramos, E.J., Meguid, M.M., Campos, A.C., Coelho, J.C., Neuropeptide Y, α-melanocyte-stimulating hormone, and monoamines in food intake regulation (2005) Nutrition, 21, pp. 269-279
• Leibowitz, S.F., Brain monoamines and peptides: Role in the control of eating behavior (1986) Fed. Proc., 45, pp. 1396-1403
• Terry, P., Gilbert, D.B., Cooper, S.J., Dopamine receptor subtype agonists and feeding behavior (1995) Obes. Res., (4 SUPPL.), pp. 515S-523S
• Hillebrand, J.J., De Wied, D., Adan, R.A., Neuropeptides, food intake and body weight regulation: A hypothalamic focus (2002) Peptides, 23, pp. 2283-2306
• Fetissov, S.O., Meguid, M.M., Sato, T., Zhang, L.H., Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake (2002) Am. J. Physiol., 283, pp. R905-R910
• Sato, T., Meguid, M.M., Fetissov, S.O., Chen, C., Zhang, L., Hypothalamic dopaminergic receptor expressions in anorexia of tumorbearing rats (2001) Am. J. Physiol., 281, pp. R1907-R1916
• Garcia-Tornadu, I., Diaz-Torga, G.S., Risso, G., Silveyra, P., Cataldi, N., Ramirez, M.C., Low, M.J., Becu-Villalobos, D., Hypothalamic orexin, OX1, α-MSH, NPY and MCRs expression in dopaminergic D2R knockout mice (2009) Neuropeptides, 43, pp. 267-274
• Sauve, D., Woodside, B., The effect of central administration of prolactin on food intake in virgin female rats is dose-dependent, occurs in the absence of ovarian hormones and the latency to onset varies with feeding regimen (1996) Brain Res., 729, pp. 75-81
• Naef, L., Woodside, B., Prolactin/leptin interactions in the control of food intake in rats (2007) Endocrinology, 148, pp. 5977-5983
• Freemark, M., Fleenor, D., Driscoll, P., Binart, N., Kelly, P.A., Body weight and fat deposition in prolactin receptor-deficient mice (2001) Endocrinology, 142, pp. 532-537
• Palmiter, R.D., Is dopamine a physiologically relevant mediator of feeding behavior? (2007) Trends Neurosci., 30, pp. 375-381
• Pijl, H., Reduced dopaminergic tone in hypothalamic neural circuits: Expression of a 'thrifty' genotype underlying the metabolic syndrome? (2003) Eur. J. Pharmacol., 480, pp. 125-131
• Fetissov, S.O., Meguid, M.M., On dopamine, D2 receptor, and Taq1A polymorphism in obesity and anorexia (2009) Nutrition, 25, pp. 132-133
• Ericson, L.E., Hakanson, R., Lundquist, I., Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion (1977) Diabetologia, 13, pp. 117-124
• Zern, R.T., Bird, J.L., Feldman, J.M., Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster (1980) Diabetologia, 18, pp. 341-346
• Baptista, T., Lacruz, A., Paez, X., Hernandez, L., Beaulieu, S., The antipsychotic drug sulpiride does not affect body weight in male rats. Is insulin resistance involved? (2002) Eur. J. Pharmacol., 447, pp. 91-98
• Ahren, B., Autonomic regulation of islet hormone secretion - Implications for health and disease (2000) Diabetologia, 43, pp. 393-410
• Nogueira, C.R., Machado, U.F., Curi, R., Carpinelli, A.R., Modulation of insulin secretion and 45Ca2+ efflux by dopamine in glucosestimulated pancreatic islets (1994) Gen. Pharmacol., 25, pp. 909-916
• Rubi, B., Ljubicic, S., Pournourmohammadi, S., Carobbio, S., Armanet, M., Bartley, C., Maechler, P., Dopamine D2-like receptors are expressed in pancreatic β cells and mediate inhibition of insulin secretion (2005) J. Biol. Chem., 280, pp. 36824-36832
• Shankar, E., Santhosh, K.T., Paulose, C.S., Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro (2006) IUBMB Life, 58, pp. 157-163
• Garcia-Tornadu, I., Ornstein, A.M., Chamson-Reig, A., Wheeler, M.B., Hill, D.J., Arany, E., Rubinstein, M., Becu-Villalobos, D., Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance (2010) Endocrinology, 151, pp. 1441-1450
• Amiel, J.M., Mangurian, C.V., Ganguli, R., Newcomer, J.W., Addressing cardiometabolic risk during treatment with antipsychotic medications (2008) Curr. Opin. Psychiatry, 21, pp. 613-618
• Newcomer, J.W., Haupt, D.W., Fucetola, R., Melson, A.K., Schweiger, J.A., Cooper, B.P., Selke, G., Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia (2002) Arch. Gen. Psychiatry, 59, pp. 337-345
• Haupt, D.W., Newcomer, J.W., Hyperglycemia and antipsychotic medications (2001) J. Clin. Psychiatry, 62 (27 SUPPL.), pp. 15-26
• Lebovitz, H.E., Metabolic consequences of atypical antipsychotic drugs (2003) Psychiatr. Q, 74, pp. 277-290
• Citrome, L., Jaffe, A., Levine, J., Allingham, B., Robinson, J., Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients (2004) Psychiatr. Serv., 55, pp. 1006-1013
• Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Kane, J.M., Shon, S., Physical health monitoring of patients with schizophrenia (2004) Am. J. Psychiatry, 161, pp. 1334-1349
• Lipscombe, L.L., Levesque, L., Gruneir, A., Fischer, H.D., Juurlink, D.N., Gill, S.S., Herrmann, N., Rochon, P.A., Antipsychotic drugs and hyperglycemia in older patients with diabetes (2009) Arch. Intern. Med., 169, pp. 1282-1289
• Rosati, G., Maioli, M., Aiello, I., Farris, A., Agnetti, V., Effects of long-term L-DOPA therapy on carbohydrate metabolism in patients with Parkinson's disease (1976) Eur. Neurol., 14, pp. 229-239

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------